SCHEMBL2215327

SCHEMBL2215327

CC(=O)NNC(=O)c1cc(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)c(F)nc1F

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 2/20 0.35
CD274 Q9NZQ7 2/20 0.35
CYP3A4 P08684 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
BRD4 O60885 1/20 0.31
MEN1 O00255 1/20 0.31
CXCR2 P25025 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
ALPL P05186 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMYD2 Q9NRG4 1/20 0.31
NPC1 O15118 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2218007 0.87 MRGPRX4 (0.32) CYP3A4KMT2ASMN1; SMN2HTTKDM4E
SCHEMBL3692210 0.81
SCHEMBL2213824 0.76 SMYD2 (0.31) CYP3A4SMN1; SMN2HTTSMYD2
SCHEMBL2306627 0.75 MAOB (0.33) KMT2AALDH1A1SMYD2
SCHEMBL5872822 0.74 MRGPRX4 (0.34) CYP3A4SMN1; SMN2HTTSMYD2
SCHEMBL2214318 0.71 SMYD2 (0.32) CYP3A4SMN1; SMN2HTTSMYD2
SCHEMBL3692211 0.70 CYP3A4 (0.31) CYP3A4SMN1; SMN2HTT
SCHEMBL1564661 0.70 HTT (0.44) HTTALDH1A1CYP2C9
SCHEMBL2213967 0.69
SCHEMBL10349815 0.68 HTT (0.37) CYP3A4SMN1; SMN2HTTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL ASTRAZENECA R&D (SE) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL TBCA, TUBA1A, BROX PDCD1 4370/4885CD274 4342/4885CYP3A4 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.